| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.50▼ | 8.51▼ | 8.50▼ | 8.58▼ | 9.30▼ |
| MA10 | 8.52▼ | 8.52▼ | 8.60▼ | 8.71▼ | 10.67▼ |
| MA20 | 8.54▼ | 8.65▼ | 8.62▼ | 9.26▼ | 11.64▼ |
| MA50 | 8.69▼ | 8.58▼ | 8.68▼ | 10.83▼ | 9.67▼ |
| MA100 | 8.60▼ | 8.72▼ | 9.01▼ | 11.62▼ | 7.33▲ |
| MA200 | 8.65▼ | 9.26▼ | 9.92▼ | 9.96▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | -0.024▼ | -0.021▼ | 0.019▲ | N/A |
| RSI | 31.521▼ | 37.888▼ | 38.675▼ | 30.439▼ | 36.284▼ |
| STOCH | 19.792▼ | 5.645▼ | 2.025▼ | 25.434 | 7.468▼ |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -87.978▼ | -95.967▼ |
| CCI | -158.390▼ | -99.029 | -101.806▼ | -72.103 | -137.792▼ |
|
Saturday, August 18, 2018 02:44 AM
Adaptimmune has several T-cell receptor projects currently being developed in-house. A recent licensing arrangement with a big pharma has seriously de-risked its flagship program, but at a price. Adap...
|
|
Thursday, August 16, 2018 09:00 AM
Get the answer today by becoming a subscriber of the Total Pharma Tracker. Company: Adaptimmune (NASDAQ:ADAP) Therapy: SPEAR T-cells Disease: Various News: ADAP announced that its safety review commit...
|
|
Wednesday, August 15, 2018 04:30 AM
PHILADELPHIA and OXFORD, United Kingdom, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a favorable review of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/08/18 | 8.79 | 8.79 | 8.45 | 8.48 | 287,750 |
| 16/08/18 | 8.69 | 8.92 | 8.44 | 8.75 | 222,057 |
| 15/08/18 | 8.48 | 8.67 | 8.26 | 8.62 | 310,624 |
| 14/08/18 | 8.60 | 8.7316 | 8.38 | 8.43 | 244,838 |
| 13/08/18 | 8.78 | 8.78 | 8.524 | 8.63 | 220,700 |
| 10/08/18 | 8.96 | 9.00 | 8.76 | 8.78 | 152,182 |
| 09/08/18 | 8.78 | 9.02 | 8.66 | 8.95 | 232,760 |
| 08/08/18 | 8.88 | 9.16 | 8.58 | 8.78 | 387,379 |
| 07/08/18 | 8.81 | 9.02 | 8.67 | 8.88 | 396,088 |
| 06/08/18 | 8.84 | 9.07 | 8.30 | 8.77 | 464,508 |
|
|
||||
|
|
||||
|
|
||||
|
|